Evidence map›Paper›PMID 24300975›Full record

ArticleBritish journal of cancer2014

Reply: 'Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'.

A Omlin, C J Pezaro, S Zaidi, D Lorente, D Mukherji, D Bianchini, R Ferraldeschi, S Sandhu, D Dearnaley, C Parker and 3 more

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

A OmlinProstate Cancer Targeted Therapy Group and Drug Development Unit, Section of Medicine, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK.
C J PezaroProstate Cancer Targeted Therapy Group and Drug Development Unit, Section of Medicine, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK.
S ZaidiAcademic Urology Unit, Sutton, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK.
D LorenteProstate Cancer Targeted Therapy Group and Drug Development Unit, Section of Medicine, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK.
D MukherjiProstate Cancer Targeted Therapy Group and Drug Development Unit, Section of Medicine, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK.
D BianchiniProstate Cancer Targeted Therapy Group and Drug Development Unit, Section of Medicine, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK.
R FerraldeschiProstate Cancer Targeted Therapy Group and Drug Development Unit, Section of Medicine, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK.
S SandhuProstate Cancer Targeted Therapy Group and Drug Development Unit, Section of Medicine, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK.
D DearnaleyAcademic Urology Unit, Sutton, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK.
C ParkerAcademic Urology Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, UK.
N Van AsAcademic Urology Unit, The Royal Marsden NHS Foundation Trust, Fulham Road, Chelsea, London, UK.
J S de BonoProstate Cancer Targeted Therapy Group and Drug Development Unit, Section of Medicine, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK.
G AttardProstate Cancer Targeted Therapy Group and Drug Development Unit, Section of Medicine, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK.

Funding

Cancer Research UK 10588Cancer Research UK 13239
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AndrostenolsAntineoplastic Combined Chemotherapy ProtocolsDiethylstilbestrolEstrogens, Non-SteroidalHumansMaleProstatic NeoplasmsSteroid 17-alpha-HydroxylaseAndrostenolsDiethylstilbestrolEstrogens, Non-SteroidalSteroid 17-alpha-Hydroxylase

Identifiers

PMID24300975
PMCPMC3887311

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.